Dr. G. Bozet, MD, Author At PanNASH

Commented Articles Epidemiology Articles

Children with suspected NAFLD: negative for other causes of liver disease

T. Yodoshi et al. (Cincinnati Children's Hospital Medical Center, USA) aimed to determine the prevalence of alternative causes of liver disease in a multicenter, retrospective cohort of 900 children with overweight and obesity patients aged ≤18 years with overweight and obesity, referred for suspected NAFLD...

September 15, 2021

Commented Articles Comorbidities Articles Epidemiology Articles NASH Observatory

Treatment of 3 major risk factors and fibrosis stage regression

Currently, no established hierarchy exists for the influence of metabolic risk factors on NAFLD progression. In this retrospective cohort study, V. J. H Yao et al. (CUNY School of Medicine/Sophie Davis Biomedical Education Program, New York, USA) investigated and ranked the independent and combined effects of three major risk...

September 13, 2021

NASH Observatory Commented Articles Pathophysiology Articles

Dynamic changes in liver macrophage subsets during NASH

Macrophage-mediated inflammation is critical in the pathogenesis of NASH. However, the underlying mechanisms remain unclear. In this study, S. Daemen et al. (Washington University School of Medicine, St. Louis, MI, USA) evaluated intra-hepatic macrophage composition in a mouse model of obesity with NAFLD and in a model of NASH...

September 8, 2021

NASH Observatory Commented Articles Epidemiology Articles

Liver transplantation indications in Saudi Arabia: NASH has eclipsed HCV

Our understanding of fatty liver syndromes and their relationship with the metabolic syndrome has improved over recent decades and, paralleling this, we are now at the dawn of the NAFLD (non-alcoholic fatty liver disease) to MAFLD (metabolic-associated fatty liver disease) transition...

September 1, 2021

NASH Observatory Commented Articles Definitions Articles

NAFLD, MAFLD, “LDE” System

Our understanding of fatty liver syndromes and their relationship with the metabolic syndrome has improved over recent decades and, paralleling this, we are now at the dawn of the NAFLD (non-alcoholic fatty liver disease) to MAFLD (metabolic-associated fatty liver disease) transition. The pitfalls of NAFLD diagnosis...

August 30, 2021

NASH Observatory Commented Articles Definitions Articles

The NAFLD-MAFLD debate

Polarising opinions and major debate have recently arisen in hepatology on the nomenclature and diagnostic criteria for fatty liver disease associated with metabolic dysfunction.The aim of this viewpoint by Y. Fouad et al. (Faculty of Medicine, Minia University, Egypt) is to suggest...

August 30, 2021

Management Articles Commented Articles NASH Observatory

Eight recommendations to improve NAFLD care models

Little attention has been given to the design and implementation of efficient and effective models of care for patients with NAFLD. In many health-care settings, no formal pathways exist, or are often not standardised according to good practices...

August 20, 2021

NASH Observatory Commented Articles Epidemiology Articles

NAFLD: a growing burden of disability

The burden of chronic liver disease varies according to aetiology and geographic location. J. M. Paik et al. (Inova Fairfax Medical Campus, Falls Church, VA, USA) assessed the global burden of disability from cirrhosis and liver cancer according to the most common aetiologies, between 2007 and 2017..

August 18, 2021

NASH Observatory Commented Articles Diagnosis Articles

Detection of HCC in patients with NAFLD

Current surveillance strategy for patients with NAFLD at risk of HCC development is unsatisfactory. G. P. Caviglia et al. (National University Health System, and Yong Loo Lin School of Medicine, National University of Singapore) aimed to investigate the diagnostic accuracy of alpha-fetoprotein (AFP), protein induced by vitamin K...

August 12, 2021

NASH Observatory Commented Articles Pathophysiology Articles

Clinical indicators for progression of NASH to cirrhosis

Providing clinicians with the tools to diagnose and treat the full spectrum of NAFLD will help prevent known complications such as cirrhosis and HCC and improve quality of life for these patients.This article by T. K. Seen et al. (Icahn School of Medicine, Elmhurst Hospital and Mount Sinai Hospital, USA) discusses...

August 10, 2021

NASH Observatory Commented Articles

Follow-up biopsy in NASH trials: 82%

The authors of this study aimed to quantify the proportion of participants with a valid follow-up biopsy in randomised clinical trials in NASH with at least 1-year follow-up. Forty-one trials were included. The proportion of participants with a valid follow-up biopsy was 82%, without evidence of a difference by location...

August 5, 2021

NASH Observatory Commented Articles

IL11 modulates hepatocyte metabolism

In this paper, J. Dong et al. (Duke-National University of Singapore Medical School, Singapore) investigate the role of IL11 in hepatocyte lipotoxicity. Their data show that IL11 modulates hepatocyte metabolism and suggests a mechanism for NAFLD to NASH transition....

August 3, 2021